Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elonide Nasal Corticosteroids in Allergic Rhinitis
NCT05912192Completed
- Sponsor
- Universiti Kebangsaan Malaysia
- Start
- Feb 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of mometasone furoate nasal spray in allergic rhinitis (AR) (3 arms), sponsored by Universiti Kebangsaan Malaysia. Primary endpoints: Change from Baseline in Symptoms Score on Allergic Rhinitis at 4 weeks, Mean difference from Baseline in Quality of Life Questionnaire at 4 weeks and 1 more. Started Feb 2022; status: completed.
02
Drugs
mometasone furoate nasal spray
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05912192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912192.